EGFR TKI Resistance Identified in a Patient with EGFR- and BRAF-Mutant Lung Adenocarcinoma

In an interview with Targeted Oncology, Brennan J. Decker, MD, PhD, discussed a real-life scenario of a patient with lung cancer who harbored both an EGFR and BRAF mutation. He highlighted the key takeaways of this case, which he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Read the full article here

Related Articles